Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | FABP3 | P05413 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 3/20 | 0.42 |
| ▸ | KCNJ6 | P48051 | 5/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288319 | 0.81 | HPGD (0.54) | CNR1CNR2HPGDFABP3FABP4 | |
| SCHEMBL22633243 | 0.81 | HPGD (0.57) | CNR1CNR2HPGDFABP3FABP4 | |
| SCHEMBL9057110 | 0.78 | CNR1 (0.49) | CNR1CNR2HPGDFABP3FABP4 | |
| SCHEMBL15319933 | 0.70 | HPGD (0.55) | CNR1CNR2HPGDKCNJ6KCNJ3 | |
| SCHEMBL29009128 | 0.69 | HCRTR1 (0.45) | CNR1CNR2HPGDNPC1RAB9A | |
| SCHEMBL29152983 | 0.69 | KMT2A (0.47) | CNR1CNR2HPGDKCNJ6KCNJ3 | |
| SCHEMBL5285406 | 0.69 | CNR1 (0.48) | CNR1CNR2FABP3FABP4KCNJ6 | |
| SCHEMBL18592035 | 0.68 | HPGD (0.49) | CNR1CNR2HPGDKCNJ6KCNJ3 | |
| SCHEMBL2850095 | 0.68 | NSD3 (0.54) | CNR1CNR2FABP3FABP4HTR2A | |
| SCHEMBL5280538 | 0.67 | KMT2A (0.48) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CNR1 3561/4885CNR2 3256/4885HPGD 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.